The CDMO Backbone

Contract Development and Manufacturing Organizations (CDMOs) are the silent engines of biotech, handling the complex scale-up of biologics and advanced therapies.

With the rise of complex modalities like mRNA, viral vectors, and cell therapies, biopharma heavily relies on outsourced manufacturing due to the intense capital requirements of building internal cGMP facilities.

Key Players

• Lonza: A global leader in biologics and cell/gene therapy manufacturing.
• Catalent: Known for formulation, clinical supply, and extensive gene therapy capabilities.
• Samsung Biologics: Massive bioreactor capacity focused heavily on monoclonal antibodies (mAbs).